What is the population in the PROTECT trial?
The population in the PROTECT trial is comprised of individuals aged 21 years, with NYHA class II-IV, left ventricular ejection fraction (LVEF) of 40%, and who have experienced a destabilisation in their condition (attended hospital or clinic for worsening heart failure). 